Ephedrine amount in labeling should be required by FDA final rule, CRN suggests.
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRINE WEIGHT LOSS CLAIMS COMPLETE BAN "INAPPROPRIATE," CRN maintains in Dec. 1 comments on FDA's June 4 proposed rule on dietary supplements containing ephedrine alkaloids. The proposed rule seeks to ban ephedrine-containing dietary supplements from recommending more than seven days of concurrent use ("The Tan Sheet" June 9. pp. 20-23). "Regarding the weight loss claim, CRN believes a complete prohibition would be inappropriate," the Council for Responsible Nutrition states. The comment period ended Dec. 2.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning